| Ytd | -78.59% | |
| 1y | -79.07% |
| Open | 1.37 | Prev Close | 1.35 | Low | 1.31 | High | 1.41 | Mkt Cap | 32.30M |
| Vol | 34.99K | Avg Vol | 253.89K | EPS | -0.97 | P/E | -1.39 | Forward P/E | N/A |
| Beta | 0.67 | Short Ratio | 0.49 | Inst. Own | 53.05% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-13 | 50-d Avg | 1.98 | 200-d Avg | 4.25 | 1yr Est | 0.00 |
ACTU News
Gainers NextCure (NASDAQ:NXTC) stock increased by 201.4% to $6.57 during Tuesday's regular sess
Gainers Agenus (NASDAQ:AGEN) shares increased by 95.8% to $6.56 during Monday's regular session
Actuate Therapeutics, Inc. (NASDAQ:ACTU), a clinical-stage biopharmaceutical company focused on deve
- BEACON2 is a landmark European multi-arm, multi-stage Phase 1/2 platform trial conducted and spons
- Patients with KRAS wild-type (WT) genomics achieved significant improvement in median overall surv
- Patients with KRAS wild-type (WT) genomics achieved significant improvement in median overall surv
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Actuate Therapeutics (NASDAQ:AC
Elraglusib oral tablet formulation to drive next-phase clinical development and broader clinical use
Elraglusib oral tablet formulation to drive next-phase clinical development and broader clinical use
Some of Wall Street's biggest upside calls are not sitting in the mega-cap names. They are hiding in
Martin Huber, MD brings deep expertise in oncology drug development, regulatory strategy, and commer
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Actuate Therapeutics (NASDAQ:AC
Twice as many advanced pancreas cancer patients who received an experimental drug developed by Actua
Actuate Therapeutics shares surged 14.41% after-hours after Nature Medicine published Phase 2 data s
Median overall survival increased by >40% in elraglusib arm compared to the control arm, with a 1
CHICAGO and FORT WORTH, Texas, April 14, 2026 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ
Top Wall Street analysts changed their outlook on top names. See all analyst rating changes, includi
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Actuate Therapeutics (NASDAQ:ACT
Meg Flippin, Benzinga Staff Writer CHICAGO, IL AND FORT WORTH, TX / ACCESS Newswire / March 24, 2026
Actuate Therapeutics (NASDAQ: ACTU - Get Free Report) and Gossamer Bio (NASDAQ: GOSS - Get Free Repo
The combination strategy is designed to simultaneously block proliferative signaling through RAS inh
CHICAGO and FORT WORTH, Texas, March 09, 2026 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ
CHICAGO and FORT WORTH, Texas, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ:
-Initiation of phase 1 portion of the trial planned in 2H 2026 -Phase 2 portion of the trial will in
CHICAGO and FORT WORTH, Texas, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ:
Actuate Therapeutics, Inc. (NASDAQ: ACTU - Get Free Report) Director Todd Thomson sold 280,000 share
CHICAGO and FORT WORTH, Texas, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ:
Actuate Therapeutics, Inc. (ACTU) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing opt
CHICAGO and FORT WORTH, Texas, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ:
The average of price targets set by Wall Street analysts indicates a potential upside of 214.1% in A
CHICAGO and FORT WORTH, Texas, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ
CHICAGO and FORT WORTH, Texas, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ